WO2000022094A3 - Procede permettant d'inhiber la modification oxydative des proteines - Google Patents

Procede permettant d'inhiber la modification oxydative des proteines Download PDF

Info

Publication number
WO2000022094A3
WO2000022094A3 PCT/US1999/023702 US9923702W WO0022094A3 WO 2000022094 A3 WO2000022094 A3 WO 2000022094A3 US 9923702 W US9923702 W US 9923702W WO 0022094 A3 WO0022094 A3 WO 0022094A3
Authority
WO
WIPO (PCT)
Prior art keywords
treat
prevent
methods
proteins
oxidative modification
Prior art date
Application number
PCT/US1999/023702
Other languages
English (en)
Other versions
WO2000022094A2 (fr
Inventor
John Baynes
Joelle Onorato
Suzanne Thorpe
Raja Khalifah
Billy Hudson
Original Assignee
Kansas University Medical Ct
Univ South Carolina
John Baynes
Joelle Onorato
Suzanne Thorpe
Raja Khalifah
Billy Hudson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kansas University Medical Ct, Univ South Carolina, John Baynes, Joelle Onorato, Suzanne Thorpe, Raja Khalifah, Billy Hudson filed Critical Kansas University Medical Ct
Priority to AU14446/00A priority Critical patent/AU1444600A/en
Publication of WO2000022094A2 publication Critical patent/WO2000022094A2/fr
Publication of WO2000022094A3 publication Critical patent/WO2000022094A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés, permettant de modéliser la formation de produits de glycosylation avancés (AGE) post-Amadori, d'identifier, et de caractériser des inhibiteurs efficaces de la formation d'AGE post-Amadori, et les compositions inhibitrices ainsi identifiées. L'invention concerne également de nouveaux procédés de traitement ou de prévention de la modification oxydative des protéines à savoir les lipoprotéines basse densité, de la peroxydation lipidique, et de l'athérosclérose, consistant à administrer une quantité efficace de l'un des composés.
PCT/US1999/023702 1998-10-09 1999-10-08 Procede permettant d'inhiber la modification oxydative des proteines WO2000022094A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14446/00A AU1444600A (en) 1998-10-09 1999-10-08 Methods for inhibiting oxidative modification of proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10379598P 1998-10-09 1998-10-09
US60/103,795 1998-10-09

Publications (2)

Publication Number Publication Date
WO2000022094A2 WO2000022094A2 (fr) 2000-04-20
WO2000022094A3 true WO2000022094A3 (fr) 2001-02-22

Family

ID=22297071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023702 WO2000022094A2 (fr) 1998-10-09 1999-10-08 Procede permettant d'inhiber la modification oxydative des proteines

Country Status (2)

Country Link
AU (1) AU1444600A (fr)
WO (1) WO2000022094A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021516A2 (fr) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Procedes destines a empecher des complications diabetiques
WO2002039994A2 (fr) 2000-11-20 2002-05-23 University Of Kansas Medical Center Methodes de traitement et de prevention des calculs urinaires
US20140235735A1 (en) * 2013-02-15 2014-08-21 Mediterranean Institute For Life Sciences Protein Damage in Aging and Age-Related Diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1093546A (en) * 1965-05-19 1967-12-06 Laroche Navarron Lab Pyridoxamine salts
DE1915497A1 (de) * 1968-03-27 1970-11-12 Inst Rech Scient Irs Arzneimittel mit hypolipidaemischer und hypocholesterinaemischer Wirksamkeit
DE2461742A1 (de) * 1974-12-28 1976-07-08 Steigerwald Arzneimittelwerk Pyridoxin-derivate sowie deren herstellung und verwendung
DE3705549A1 (de) * 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
CA2055990A1 (fr) * 1990-11-22 1992-05-23 David G. Schena Derives de vitamines phospholipidiques et methodes de preparation
WO1999025690A2 (fr) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Intermediaires de produits terminaux de glycosylation avancee et inhibition post-amadori

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1093546A (en) * 1965-05-19 1967-12-06 Laroche Navarron Lab Pyridoxamine salts
DE1915497A1 (de) * 1968-03-27 1970-11-12 Inst Rech Scient Irs Arzneimittel mit hypolipidaemischer und hypocholesterinaemischer Wirksamkeit
DE2461742A1 (de) * 1974-12-28 1976-07-08 Steigerwald Arzneimittelwerk Pyridoxin-derivate sowie deren herstellung und verwendung
DE3705549A1 (de) * 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
CA2055990A1 (fr) * 1990-11-22 1992-05-23 David G. Schena Derives de vitamines phospholipidiques et methodes de preparation
WO1999025690A2 (fr) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Intermediaires de produits terminaux de glycosylation avancee et inhibition post-amadori

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOOTH A A ET AL: "IN VITRO KINETIC STUDIES OF FORMATION OF ANTIGENIC ADVANCED GLYCATION END PRODUCTS (AGES)", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 9, 28 February 1997 (1997-02-28), pages 5430 - 5437, XP002068236, ISSN: 0021-9258 *
BOOTH A A ET AL: "THIAMINE PYROPHOSPHATE AND PYRIDOXAMINE INHIBIT THE FORMATION OF ANTIGENIC ADVANCED GLYCATION END-PRODUCTS: COMPARISON WITH AMINOGUANIDINE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 220, no. 1, 1 January 1996 (1996-01-01), pages 113 - 119, XP002024845, ISSN: 0006-291X *
JACKSON R L: "ANTI-OXIDANTS FOR THE TREATMENT AND THE PREVENTION OF ATHEROSCLEROSIS", BIOCHEMICAL SOCIETY TRANSACTIONS,GB,COLCHESTER, ESSEX, vol. 21, no. 3, 1 August 1993 (1993-08-01), pages 650 - 651, XP000567472, ISSN: 0300-5127 *
RATH M. ET AL: "Nutritional supplement program halts progression of early coronary atherosclerosis documented by ultrafast computed tomography.", JOURNAL OF APPLIED NUTRITION, (1996) 48/3 (68-78)., XP000914195 *

Also Published As

Publication number Publication date
WO2000022094A2 (fr) 2000-04-20
AU1444600A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
EP0772590A1 (fr) Inhibiteurs de la thrombine
IL126404A0 (en) Pyrazinone thrombin inhibitors
PL330782A1 (en) Method of treating carcinoma using the inhibitors of naaladase
AU6513701A (en) Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
NO912630D0 (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler.
WO2001005392A3 (fr) Traitement des douleurs chroniques par des inhibiteurs de mek
AU3095601A (en) O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
AP9901464A0 (en) Method of treating heart failure.
WO2001005390A3 (fr) Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek
ID27838A (id) Inhibitor 1,2,3,4-tetrahidrokinolin tersubstitusi 2-tersubstitusi 4-amino sebagai inhibitor cetp
EP0768087A3 (fr) Traitement pour le sevrage de drogues
AU5759899A (en) Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
AU2898297A (en) Use of substance p antagonists for treating social phobia
WO2000034468A3 (fr) Antagonistes de la muc-1 et methodes de traitement de troubles immunitaires
WO2000022094A3 (fr) Procede permettant d'inhiber la modification oxydative des proteines
WO2000023063A3 (fr) Procedes pour inhiber les complications diabetiques
IL98711A0 (en) Bis(4-(2.6-di-alkyl)phenol)silane derivatives as antiatherosclerotic agents
WO2000021516A3 (fr) Procedes destines a empecher des complications diabetiques
DE69620325T2 (de) Methode der Pulverisierung aromatischer Phosphate
PL345467A1 (en) Method of treating pulmonary hypertension
AU5058393A (en) Novel 2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
FI20001542A (fi) Menetelmä septisen sokin hoitamiseksi
AU5781199A (en) Method for the prevention of unauthorized duplication of information-carrying substrates
AU1244299A (en) Method for thermo-mechanical treatment of damaged or waterlogged natural timber
GB9800688D0 (en) 2,3,5-trisubsitiuted pyridines as inhibitors of cyclooxygenase-2

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14446

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase